Prevalence of the Metabolic Syndrome and Its Components

Findings from a Finnish general population sample and the Diabetes Prevention Study cohort

PIRJO ILANNE-PARIKKA, MD1,2
JOHAN G. ERIKSSON, MD, PHD3
JAANA LINDSTRÖM, MS3
HELENA HÄMÄLÄINEN, MD, PHD4
SIRKKA KEINÄNEN-KIUKAANNIEMI, MD, PHD5,6
MAURI LAAKSO, MD5,6
ANNE LOUHERANTA, PHD7
MARJO MANNELIN, MS9
MERJA RASTAS, MS3

VIRPI SALMINEN, MS3
SIRKKA AUNOLA, PHD9
JOUKO SUNDVALL, MS10
TIMO VALLE, MD3
JORMA LAHTELA, MD, PHD2
MATTI UUSITUPA, MD, PHD7
JAAKKO TUOMILEHTO, MD, PHD3

ON BEHALF OF THE FINNISH DIABETES PREVENTION STUDY GROUP

OBJECTIVE — To assess the prevalence of the metabolic syndrome (MetS) in two independent Finnish study cohorts.

RESEARCH DESIGN AND METHODS — The prevalence of the MetS by modified World Health Organization criteria was analyzed in different categories of glucose tolerance in a cross-sectional, population-based sample of 2,049 individuals (FINRISK) aged 45–64 years and in 522 participants of the Finnish Diabetes Prevention Study (DPS) with impaired glucose tolerance (IGT).

RESULTS — In the FINRISK cohort, the MetS was present in 38.8% of the men and 22.2% of the women. The prevalence was 14.4 and 10.1% in subjects with normal glucose tolerance, 74.0 and 52.2% in subjects with impaired fasting glucose, 84.8 and 65.4% in subjects with IGT, and 91.5 and 82.7% in subjects with type 2 diabetes in men and women, respectively. Among women, the prevalence of the MetS increased with increasing age. In the DPS cohort, the MetS was present in 78.4% of the men and 72.2% of the women with IGT.

CONCLUSIONS — The MetS was extremely common in middle-aged subjects. The high prevalence in men was mostly due to their high waist-to-hip ratio. The prevalence of the MetS increased in both sexes with deterioration in glucose regulation. Approximately 75% of the subjects with IGT had the MetS. Because the syndrome includes the major risk factors for cardiovascular disorders and is the major antecedent for type 2 diabetes, concerted preventive action should be targeted to control all the features of the MetS.

The prevalence of type 2 diabetes is rapidly increasing worldwide (1,2), primarily due to the global increase in obesity and sedentary lifestyles (3). Subjects with impaired glucose tolerance (IGT) are at increased risk of developing type 2 diabetes and form an important high-risk group for actions aimed at preventing the disease (4–7).

Subjects with abnormal glucose metabolism are at increased risk for cardiovascular disorders and often exhibit various cardiovascular risk factors (8). The clustering of cardiovascular risk factors has been called the metabolic syndrome (MetS). Currently there are four definitions: the criteria of the World Health Organization (WHO) consultation (9), the criteria of the European Group for the Study of Insulin Resistance (EGIR) (10), the criteria of the National Cholesterol Education Program (NCEP) Expert Panel (11), and the criteria of the American Association of Clinical Endocrinologists (12).

Type 2 diabetes and IGT are closely associated with the MetS (13). Clustering of the risk factors associated with this syndrome predicts the development of manifest diabetes and cardiovascular disease (14–20). Prevention of type 2 diabetes should therefore aim to prevent and treat several components of the MetS simultaneously.

The aim of this study was to assess the prevalence and clustering of components of the MetS using the WHO criteria in two independent middle-aged Finnish study cohorts: the population-based FINRISK study cohort and the participants of the Finnish Diabetes Prevention Study (DPS).
RESEARCH DESIGN AND METHODS — The FINRISK survey took place in spring 1992 as part of the FINMONICA cardiovascular risk factor survey. The survey methods followed the WHO MONICA protocol (21) and are detailed elsewhere (22,23). In brief, a cross-sectional stratified random sample of 8,000 subjects aged 25–64 years from four regions of Finland was drawn from the national population register. A subsample of 3,300 individuals aged 45–64 years was formed to assess glucose metabolism; 3,201 of these subjects completed a postal questionnaire on medical history and made their first study visit. Clinical and metabolic characteristics related to blood pressure and dyslipidemia were analyzed in the present study. A total of 2,087 attended a second visit for a standard 75-g oral glucose tolerance test (OGTT) (24). Glucose status could be classified in 2,061 subjects, based on current use of diabetes medication (n = 71), fasting plasma glucose (FPG) value (n = 88), or OGTT value (n = 1902). After excluding type 1 diabetic patients (n = 12) from the assessment, 2,049 subjects were included in the further analysis of glucose tolerance and components of the MetS, representing 62% of the original 3,300 subjects.

The DPS was a randomized prospective controlled trial to assess the possibility of preventing type 2 diabetes by lifestyle intervention (25,26). The design of the DPS is described in detail elsewhere (27). Briefly, 522 overweight subjects (BMI ≥25 kg/m²) aged 40–65 years and with IGT participated. The definition of IGT was based on the mean of two consecutive 2-h glucose values in OGTT (24). The Ethics Committee of Finland’s National Public Health Institute approved the study protocol. All subjects gave written informed consent.

Both studies involved similar investigations, including a self-administered questionnaire, medical history, physical examination, and laboratory examinations. Those taking medication during the past week were recorded as being on medication. Blood pressure was measured from the right arm of the subject seated for 5 min before measurement. Systolic and diastolic blood pressure values were recorded as the mean of two measurements.

In FINNRISK, fasting and 2-h blood samples for plasma glucose were measured at the local laboratory by a hexokinase method. In the DPS, the plasma glucose concentrations during the OGTT were determined locally and confirmed at a central laboratory in Helsinki. All other blood samples in both studies were analyzed in the same central laboratory (National Public Health Institute, Helsinki). Cholesterol and triglyceride levels were determined by enzymatic assays (Boehringer Mannheim, Mannheim, Germany). HDL cholesterol was measured after dextran sulfate magnesium chloride precipitation of apo B-containing lipoproteins.

Serum insulin was measured by a radioimmunoassay method (Pharmacia, Upsala, Sweden). The intra-assay coefficient of variation (CV) for serum insulin was 5.3%, and the interassay CV was 7.6%.

Definitions of the MetS and its components
For the definition of the MetS, we used the WHO criteria (9) modified as follows: insulin resistance was defined by the top quartile distribution of fasting insulin among subjects without diabetes (10). Top quartile cutoff points were 9.42 and 9.80 μU/l for men and 8.20 and 9.75 μU/l for women in age-groups of 45–54 and 55–64 years, respectively. Different categories of glucose tolerance were calculated applying the WHO 1999 criteria (9) in venous plasma samples as follows: normal glucose tolerance (NGT): FPG <6.1 mmol/l and 2-h plasma glucose <7.8 mmol/l; impaired fasting glycemia (IFG): FPG 6.1–6.9 mmol/l and 2-h plasma glucose <7.8 mmol/l; impaired glucose tolerance (IGT): FPG <7.0 mmol/l and 2-h plasma glucose 7.8–11.0 mmol/l; diabetes: FPG ≥7.0 mmol/l or 2-h PG ≥11.1 mmol/l, or current use of diabetes medication. Subjects were considered to have obesity if waist-to-hip ratio (WHR) was >0.90 in men and >0.85 in women and/or BMI was ≥30 kg/m². Subjects were considered to have hypertension if blood pressure was ≥140/90 mmHg or if they were taking antihypertensive medication. Subjects were considered to have dyslipidemia if plasma triglyceride was ≥1.7 mmol/l and/or HDL cholesterol was <0.9 mmol/l for men and <1.0 mmol/l for women, or if they were using lipid-lowering medication.

A subject was considered to have the MetS if they had either NGT with insulin resistance, IFG, IGT, or diabetes and two or more of the following features: obesity, hypertension, or dyslipidemia.

Statistical analysis
The data were analyzed using statistical software (SPSS version 11.5; SPSS, Chicago, IL). Continuous numerical variables are presented as means ± SD unless otherwise indicated. The analysis included independent samples two-tailed t test for equality of means between sexes for variables distributed normally. Fasting serum insulin, 2-h serum insulin, and triglycerides were skewed, and the Mann-Whitney U test was used for them. The χ² test was used to analyze the dependency of categorical variables.

RESULTS — The clinical and metabolic characteristics of the 3,201 subjects are presented in Table 1. The men had higher waist circumference, WHR, diastolic blood pressure, LDL cholesterol, and triglycerides but lower HDL cholesterol than the women. There was no marked sex difference in the proportion of those having BMI ≥30 kg/m². However, in terms of abdominal obesity, 78.1% of the men had WHR >0.9, whereas only 23.6% of the women had WHR >0.85. The prevalences of hypertension and dyslipidemia were significantly higher in men.

Drop outs
The men who failed to attend (n = 602, 39.1%) the second visit for the glucose tolerance assessment were slightly younger (53.5 vs. 54.7 years) and slimmer. Nevertheless, the prevalences of obesity (77.5 vs. 80.0%; P = 0.252), hypertension (65.1 vs. 66.6%; P = 0.560), and dyslipidemia (50.2 vs. 48.0%; P = 0.40) were similar in nonattenders and attenders. In contrast, the female nonattenders (n = 550, 33.1%) had significantly higher systolic blood pressure (145.8 vs. 140.7 mmHg; P < 0.001), higher prevalences of obesity (39.0 vs. 33.4%; P = 0.026), hypertension (63.8 vs. 55.2%; P = 0.001), and dyslipidemia (30.9 vs. 25.1%; P = 0.013).

Prevalence of insulin resistance and disturbances in glucose metabolism
Insulin resistance in subjects with NGT was present in 10.8% of the men and 15.1% of the woman. The prevalence of disturbances in glucose metabolism by sex and age-group is presented in Table 2.
Abnormal glucose metabolism was found in 34.9% of the men and 21.3% of the women. The men had significantly higher prevalences of IFG and diabetes than the women. Diabetes was found in 10.1 and 6.8% of the men and women, respectively, whereas according to the questionnaires only 37.2% of the subjects with diabetic blood glucose values were aware of the condition.

Table 2—Prevalence (%) of MetS and its components in the glucose tolerance study subgroup (n = 2,049) of the FINRISK cohort by sex and age-group

<table>
<thead>
<tr>
<th></th>
<th>Men</th>
<th>Women</th>
<th>P between sexes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>45–54 years</td>
<td>55–64 years</td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>427</td>
<td>509</td>
<td></td>
</tr>
<tr>
<td>MetS</td>
<td>36.2</td>
<td>41.4</td>
<td>0.116</td>
</tr>
<tr>
<td>NGT with insulin resistance</td>
<td>12.2</td>
<td>9.5</td>
<td>0.194</td>
</tr>
<tr>
<td>IFG</td>
<td>14.5</td>
<td>12.4</td>
<td>0.337</td>
</tr>
<tr>
<td>IGT</td>
<td>8.9</td>
<td>13.8</td>
<td>0.021</td>
</tr>
<tr>
<td>Diabetes</td>
<td>7.5</td>
<td>12.6</td>
<td>0.104</td>
</tr>
<tr>
<td>Obesity</td>
<td>77.6</td>
<td>81.9</td>
<td>0.104</td>
</tr>
<tr>
<td>BMI &gt;30 kg/m²</td>
<td>26.5</td>
<td>26.5</td>
<td>0.984</td>
</tr>
<tr>
<td>Abdominal obesity</td>
<td>76.9</td>
<td>80.9</td>
<td>0.134</td>
</tr>
<tr>
<td>Hypertension</td>
<td>60.7</td>
<td>71.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic blood pressure ≥140 mmHg</td>
<td>46.6</td>
<td>62.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diastolic blood pressure ≥90 mmHg</td>
<td>44.3</td>
<td>42.1</td>
<td>0.459</td>
</tr>
<tr>
<td>Use of antihypertensive medication</td>
<td>15.0</td>
<td>20.6</td>
<td>0.010</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>51.7</td>
<td>53.0</td>
<td>0.712</td>
</tr>
<tr>
<td>Low HDL cholesterol (men &lt;0.9 women &lt;1.0 mmol/l)</td>
<td>9.4</td>
<td>14.0</td>
<td>0.029</td>
</tr>
<tr>
<td>Triglycerides ≥1.7 (mmol/l)</td>
<td>44.7</td>
<td>45.6</td>
<td>0.799</td>
</tr>
<tr>
<td>Use of lipid-lowering medication</td>
<td>3.5</td>
<td>5.0</td>
<td>0.285</td>
</tr>
</tbody>
</table>

Obesity: BMI >30 kg/m² or WHR >0.9 in men and >0.85 in women. Abdominal obesity: WHR >0.9 in men and >0.85 in women. Hypertension: systolic ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of antihypertensive medication. Dyslipidemia: triglycerides ≥1.7 mmol/l or HDL cholesterol <0.9 in men and <1.0 mmol/l in women or use of lipid-lowering medication.
men, and higher triglycerides in women were significantly more common in the 55- to 64-year age-group.

**Prevalence of MetS in different categories of glucose tolerance**

The MetS was observed in 12.3% of the subjects with NGT, in 63.1% with IFG, in 75.1% with IGT, and in 87.1% with diabetes. The prevalence of the MetS and its components in different categories of glucose metabolism is presented in Table 3. In all categories men had a higher prevalence of obesity and dyslipidemia than women. The MetS clustered most often together with obesity in all categories of glucose tolerance in men. In women it clustered most often with hypertension in NGT, IFG, and IGT categories but with obesity in those with diabetes.

**The DPS cohort**

The clinical and metabolic characteristics of the 522 DPS subjects with IGT and overweight are presented in Table 4. Mean BMI was significantly higher in women than men, but WHR was significantly higher in men. Men had slightly higher diastolic blood pressure and FPG, but lower HDL cholesterol. Altogether, 78.4% of the men and 72.2% of the women fulfilled the criteria for MetS. Obesity was seen in 96.5 and 66.3%, hypertension in 62.9 and 60.9%, and dyslipidemia in 51.2 and 48.6% of men and women, respectively.

**CONCLUSIONS** — In the FINRISK cohort of people aged 45–64 years, ~40% of the men and ~20% of women fulfilled the modified WHO criteria for the MetS. Among women the prevalence of the MetS increased with increasing age. The high prevalence among men was closely associated with abdominal obesity. If we had used only BMI >30 kg/m² for the criteria of obesity instead of high WHR or high BMI, the prevalence of the MetS would have been lower (~30%) in men but would have stayed in the same range in women. Our study conforms with the range found in other studies on Caucasian people. In general the MetS is observed in 15–30% of middle-aged people in industrialized western countries (8.28–31).

Our FINRISK cohort represented 62% of the original randomized, age- and sex-stratified, population-based FINRISK study cohort. The prevalences of obesity,
hypertension, and dyslipidemia were similar in the men who did or did not attend the glucose tolerance study, which strengthens reliability of the results. In contrast, all the components were more prevalent in the female nonattenders of the glucose tolerance study, which could have caused underestimation of the prevalence of the MetS in women.

Impaired glucose regulation was closely associated with the syndrome. The prevalence of the MetS increased with established abnormalities in glucose metabolism from 12% in the subjects with NGT to 87% in those with manifest diabetes. The prevalence of the MetS was high and fairly similar in both study cohorts among those with IGT: 75% in the FINRISK and 73% in the DPS. The prevalence was higher among men in all categories of glucose tolerance and also increased with age, which is in accordance with previous studies. In the Finnish Bornia study, the MetS applying the WHO definition, was diagnosed in 10 and 15% of subjects with NGT, 42 and 64% of those with IGT, and 78 and 84% of those with type 2 diabetes in women and men, respectively (13). EGIR also found that the frequency of MetS by both WHO and EGIR definitions increased with age and was almost always higher in men than in women at a given age (31). In the Bruneck Study, the prevalence of insulin resistance syndrome in subjects aged 40–79 years was 66% in subjects with IGT and 84% among those with type 2 diabetes (32).

Different features of the MetS were surprisingly common in middle-aged individuals in the general population, especially in men. Obesity, hypertension, and dyslipidemia were all significantly more common among men. The high prevalence of obesity in men seemed to be due to their high WHR. Obesity, defined as high WHR (~78%), was clearly more common than obesity defined as BMI >30 kg/m² (~25%) in men, while both prevalences were quite similar in women (~25%). Over half of the men and women had hypertension, which is in accordance with the European cohorts published by EGIR (31). There were differences in the clustering of the components according to glucose status in men and women: whereas obesity was significantly more common among men than among women in all categories of glucose tolerance, the difference in the prevalence of hypertension and dyslipidemia between sexes declined with deteriorating glucose metabolism. The prevalence of dyslipidemia was more dependent on the presence of elevated triglycerides than of low HDL cholesterol.

In the FINRISK study, milder disturbances in glucose metabolism were quite common, especially in men: IFG or IGT was present in ~25% of the men and ~15% of the women. Around 10% had diabetes, but it was undiagnosed in over half of the cases.

Type 2 diabetes is preceded by a long period of milder disturbances in glucose metabolism (3). The Finnish DPS (26) and the Diabetes Prevention Program (33) in the U.S. have shown that the incidence of diabetes can be reduced by 38% with lifestyle changes in subjects with IGT. While the clustering of risk factors related to insulin resistance is an important predictor of the development of manifest diabetes, early ascertainment of the MetS in normal clinical consultation would prove useful for identifying those at risk.

In conclusion, the prevalence of the MetS in this Finnish setting was common in middle-aged subjects, especially men, and increased with age and worsening glucose metabolism. Our results support previous findings: the overall prevalence of MetS was ~30% in the population-based cohort and ~75% in subjects with IGT. The DPS study cohort, although comprised of volunteers for an intervention study, was quite similar to the IGT subjects in the Finnish general population. While prevention of type 2 diabetes also aims to minimize the associated vascular complications, preventive actions should focus on not only improving glucose tolerance but also on preventing and treating all components of the MetS.

Acknowledgments — This study was supported by grants from the Finnish Academy (grants 847/2298, 40758/5767, 38387/54175, and 46358), the Ministry of Education, the Novo Nordisk Foundation, the Yrjö Jahnsson Foundation, the Juho Vainio Foundation, the Finnish Diabetes Research Foundation, and EVO funds from Pirkkannaa Hospital District and Kuopio University Hospital.

References


